Related references
Note: Only part of the references are listed.Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial
Mohan Suntharalingam et al.
JAMA ONCOLOGY (2017)
The Global Burden of Esophageal Cancer: A Disability-Adjusted Life-Year Approach
Benjamin J. Di Pardo et al.
WORLD JOURNAL OF SURGERY (2016)
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries
Maria Jose Domper Arnal et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma: a retrospective analysis of 426 cases
Hailu Chen et al.
MEDICAL ONCOLOGY (2015)
Epidemiological Characteristics and Prediction of Esophageal Cancer Mortality in China from 1991 to 2012
Wen-Rui Tang et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Jianguo Feng et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Role of SPARC in Bone Remodeling and Cancer-Related Bone Metastasis
Nilza Ribeiro et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2014)
Adjuvant Chemotherapy After Esophagectomy: Is There a Role in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma?
Xiao Lyu et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action
Salah-Eddin Al-Batran et al.
ONCOLOGY RESEARCH AND TREATMENT (2014)
NUMBER AND LOCATION OF POSITIVE NODES, POSTOPERATIVE RADIOTHERAPY, AND SURVIVAL AFTER ESOPHAGECTOMY WITH THREE-FIELD LYMPH NODE DISSECTION FOR THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Junqiang Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer
M. Kranzfelder et al.
BRITISH JOURNAL OF SURGERY (2011)
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
Katrin M. Sjoquist et al.
LANCET ONCOLOGY (2011)
Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
Koichi Azuma et al.
LUNG CANCER (2009)
Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer
David P. Kelsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL(R)-free formulation of paclitaxel
Thomas E. Stinchcombe
NANOMEDICINE (2007)
Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients
G Ferrandina et al.
CLINICAL CANCER RESEARCH (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
P Sève et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer
Angelo Paradiso et al.
ANNALS OF ONCOLOGY (2005)
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204
N Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury
AD Bradshaw et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Share Paper
